Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-004809-40
    Sponsor's Protocol Code Number:GV1001-AD-CL2-007
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-11-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-004809-40
    A.3Full title of the trial
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease
    Studio clinico prospettico di fase 2 di 52 settimane, multicentrico, randomizzato, in doppio cieco, controllato con placebo, con disegno a gruppi paralleli per valutare la sicurezza e l’efficacia di GV1001 somministrato per via sottocutanea per il trattamento della malattia di Alzheimer da lieve a moderata
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    GV1001 CS for the Treatment of Mild to Moderate Alzheimer's Disease
    GV1001 SC per il trattamento della malattia di Alzheimer da lieve a moderata
    A.3.2Name or abbreviated title of the trial where available
    NA
    NA
    A.4.1Sponsor's protocol code numberGV1001-AD-CL2-007
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGemVax & KAEL Co., Ltd.
    B.1.3.4CountryKorea, Republic of
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGemVax
    B.4.2CountryKorea, Republic of
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGemVax&KAEL Co., Ltd.
    B.5.2Functional name of contact pointJeongmi Kim
    B.5.3 Address:
    B.5.3.1Street Address3fl, 117 Unjung-ro
    B.5.3.2Town/ cityBundang-gu, Seongman-si, Gyeonggi-do
    B.5.3.3Post code13461
    B.5.3.4CountryKorea, Republic of
    B.5.4Telephone number+827086521807
    B.5.6E-mailjeongmikim@gemvax.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGV1001
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTertomotide
    D.3.9.1CAS number 922174-60-5
    D.3.9.2Current sponsor codeA001
    D.3.9.4EV Substance CodeSUB189146
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.84
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGV1001
    D.3.2Product code [na]
    D.3.4Pharmaceutical form Lyophilisate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTertomotide
    D.3.9.1CAS number 922174-60-5
    D.3.9.2Current sponsor codeA001
    D.3.9.4EV Substance CodeSUB189146
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1.68
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboConcentrate and solvent for solution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Mild to Moderate (stage 4 and 5) Alzheimer's Disease
    Morbo di Alzheimer da lieve a moderato (stadio 4 e 5).
    E.1.1.1Medical condition in easily understood language
    Alzheimer's Disease
    Mordo di Alzheimer
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10001896
    E.1.2Term Alzheimer's disease
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    -To evaluate the efficacy of GV1001 (0.56 mg and 1.12 mg) relative to placebo on cognition in participants with mild to moderate AD, as measured by ADAS-cog11
    -To evaluate the safety of GV1001 in participants with mild to moderate AD
    - Valutare l’efficacia di GV1001 (0,56 mg e 1,12 mg) rispetto al placebo sulla cognizione nei partecipanti con AD da lieve a moderata, misurata mediante ADAS-cog11
    - Valutare la sicurezza di GV1001 in partecipanti con AD da lieve a moderata
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of GV1001 (0.56 mg and 1.12 mg) relative to placebo on cognition and function in participants with mild to moderate AD, as measured by:
    ADAS-cog11
    A-AIADL-Q
    NPI
    MMSE
    CDR-SB
    ADCS-CGIC/CIBIC Plus
    QoL-AD
    Valutare l’efficacia di GV1001 (0,56 mg e 1,12 mg) rispetto al placebo sulla cognizione e funzione in partecipanti con AD da lieve a moderata, misurata mediante:
    ADAS-cog11
    A-AIADL-Q
    NPI
    MMSE
    CDR-SB
    ADCS-CGIC/CIBIC Plus
    QoL-AD
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female participants 55 to 85 years of age (both inclusive) at the time of signing the informed consent.
    2. Diagnosis of probable AD based on NINCDS-ADRDA criteria (a and b) as determined by a neurologist, geriatrician, psychiatrist, or clinician approved by the Sponsor or designee.
    a. Presence of an early and significant episodic memory impairment that includes the following features:
    • Gradual and progressive change in memory function reported by patients or informants over > 6 months
    • Objective evidence of significantly impaired episodic memory on testing: this generally consists of recall deficit that does not improve significantly or does not normalize with cueing or recognition testing and after effective encoding of information has been previously controlled
    • The episodic memory impairment can be isolated orassociated with other cognitive changes at the onset or AD or as AD advanced
    b. One or more findings for probable AD by either MRI, Aß PET scan, historical CSF results, or a historical genetic test in the 2 years before screening, or an MRI or Aß PET scan a screening. The MRI must have findings consistent with ADand without any other disease that may cause dementia. The Aß PET scan and historical CSF results must be consistent with the presence of amyloid pathology
    3. Mild or moderate dementia as evidenced by MMSE score =13 to =24 at screening (Visit 1).
    4. Not applicable
    5. Not applicable
    6. If receiving an approved medication for AD (ie, donepezil, galantamine, rivastigmine, memantine, or memantine/donepezil combination product), must be on the medication with a stable dose for
    at least 12 weeks before the screening visit (dosing should remain stable throughout the study).
    7. If receiving an OTC supplement for cognition (eg, gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin), must not be exceeding the recommended dose for at least 12 weeks prior to screening visit.
    8. Able to visit the study center and undergo cognitive, functional, and other tests specified in the protocol.
    9. Has a caregiver who:
    Agrees to accompany the participant to all study visits and able to supervise the participant’s compliance with the study procedures and provide detailed information about the participant
    Either lives with the participant or sees the participant on average for =1 hour/day =3 days/week, or in the Investigator’s opinion, the extent of contact is sufficient to provide meaningful assessment of changes in participant behaviour and function over time and provide informationon safety and tolerability
    Is able to read, understand, and speak the designated language at the study center.
    Caregiver must be cognitively able to fulfill the requirements of the study
    10. A male participant must agree to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment and refrain from donating sperm during this period
    11. a female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR
    A WOCBP who agrees to use a highly effective contraception method during the treatment period and for at least 3 months after the last dose of study treatment
    12. A WOCBP must have a negative serum pregnancy test at screening (Visit 1) and a negative urine pregnancy test at Visit 2 before randomization, and must use medically accepted means of contraception throughout the study.
    13. Written informed consent provided by participant (or legal representative) and caregiver prior to any study-specific procedures.
    1. partecipanti di sesso maschile o femminile di età compresa tra 55 e 85 anni (entrambi inclusi) al momento della firma del consenso informato;
    2. diagnosi di probabile AD in base ai criteri NINCDS-ADRDA (a e b) come stabilito da un neurologo, geriatra, psichiatra o medico approvato dallo Sponsor o dall’incaricato;
    a.Presenza di una compromissione della memoria episodica precoce e significativa che include le seguenti caratteristiche:
    • Cambiamenti graduali e progressivi nella funzione della memoria riferiti da pazienti o informatori in > 6 mesi
    • Evidenza obiettiva di memoria episodica significativamente compromessa al test: generalmente consiste in un deficit di richiamo che non migliora in modo significativo o non si normalizza con il test di cueing o riconoscimento e dopo che l'effettiva codifica delle informazioni è stata precedentemente controllata
    • La compromissione della memoria episodica può essere isolata o associata ad altri cambiamenti cognitivi all'esordio o all'AD o con l'avanzare dell'AD
    b. Uno o più riscontri di probabile AD mediante risonanza magnetica, scansione Aß PET, risultati storici del liquido cerebrospinale o un test genetico storico nei 2 anni precedenti lo screening, oppure una scansione MRI o Aß PET uno screening. La risonanza magnetica deve avere risultati coerenti con l'AD e senza altre malattie che possono causare demenza. La scansione Aß PET e i risultati storici del CSF devono essere coerenti con la presenza di patologia amiloide
    3. demenza lieve o moderata come evidenziato da punteggio MMSE da =13 a =24 allo screening (Visita 1);
    4. non applicabile
    5. non applicabile
    6. in caso di ricezione di un farmaco approvato per l’AD (es., donepezil, galantamina, rivastigmina, memantina, o il prodotto in combinazione memantina/donepezil), deve trattarsi di un trattamento con dose stabile da almeno 12 settimane prima della visita di screening (il dosaggio deve rimanere stabile per tutta la durata dello studio);
    7. in caso di ricezione di un integratore OTC per i processi cognitivi (es., gingko biloba, omega-3 acidi grassi polinsaturi, vitamine E, curcumina), la dose non deve superare quella raccomandata per almeno 12 settimane prima della visita di screening;
    8. capacità di recarsi al centro dello studio e sottoporsi ai test cognitivi, funzionali e agli altri test specificati nel protocollo;
    9. Ha una caregiver che:
    Accetta di accompagnare il partecipante a tutte le visite di studio ed è in grado di supervisionare la conformità del partecipante alle procedure dello studio e di fornire informazioni dettagliate sul partecipante
    O vive con il partecipante o vede il partecipante in media per =1 ora/giorno =3 giorni/settimana, o secondo l'opinione dello sperimentatore, l'estensione del contatto è sufficiente per fornire una valutazione significativa dei cambiamenti nel comportamento e nella funzione del partecipante nel tempo e fornire informazioni sulla sicurezza e tollerabilità
    È in grado di leggere, comprendere e parlare la lingua designata presso il centro studi.
    Il caregiver deve essere cognitivamente in grado di soddisfare i requisiti dello studio
    10. Un partecipante maschio deve accettare di utilizzare un metodo contraccettivo altamente efficace durante il periodo di trattamento e per almeno 3 mesi dopo l'ultima dose del trattamento in studio e astenersi dal donare sperma durante questo periodo
    11. una partecipante di sesso femminile è idonea a partecipare se non è incinta, non sta allattando e si applica almeno una delle seguenti condizioni: Non è una donna in età fertile (WOCBP) OPPURE
    Un WOCBP che accetta di utilizzare un metodo contraccettivo altamente efficace durante il periodo di trattamento e per almeno 3 mesi dopo l'ultima dose del trattamento in studio
    12. le donne in età fertile devono risultare negative al test di gravidanza sul siero allo screening (Visita 1) e negative al test di gravidanza sulle urine alla Visita 2 prima della randomizzazione, e devono utilizzare metodi contraccettivi clinicamente accettati per tutta la durata dello studio;
    13. consenso informato scritto fornito dal/dalla partecipante (o dal rappresentante legale) e dal caregiver prima di qualsiasi procedura specifica per lo studio.
    E.4Principal exclusion criteria
    1. Any other cause of dementia shown by MRI/CT findings within 2 years of screening (or at screening) and neurological examination at screening and Day 1
    • Possible, probable, or definite vascular dementia according to the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche’ et l’Enseignement en Neurosciences (NINDS-AIREN) criteria.
    • Evidence of significant abnormality that would suggest another potential etiology for dementia (eg evidence of cerebral contusion, encephalomalacia, aneurysm, vascular malformation, >5 microhemorrhages, macrohemorrhage, single infart >1 cm3).
    • Other central nervous system diseases including cerebrovascular dementia, Parkinsonism, Huntington’s disease, subdural hematoma, normal pressure hydrocephalus, brain tumor, Creutzfeldt-Jakob disease)
    2. Concurrent or history of schizophrenia or bipolar disorder; or any other clinically significant psychiatric conditions (eg, schizophrenia or bipolar affective disorder) that in the Investigator's opinion prevents the participant from participating, or is likely to confound interpretation of drug effect or affect cognitive assessments or participant safety; OR the presence or history of suicidal attempts or suicidal ideation evidenced by endorsing Items 4 or 5 of the C-SSRS at screening or Day 1, endorsing any suicidal behaviour item on the C-SSRS Since Last Visit form on Day 1, or any suicide attempt within 2 years prior to screening.
    3. Vitamin B12, folic acid, syphilis serology, and thyroid stimulating hormone (TSH) results that are thought to contribute to the severity of dementia or cause dementia. Participants may be enrolled if in the Investigator's medical judgment, the abnormal laboratory values are not the cause of the cognitive symptoms.
    4. History of known or suspected seizures including febrile seizures (excluding self-limited childhood febrile seizures), a history of significant head trauma with loss of consciousness or recent unconsciousness that is not explained.
    5. Acute or unstable cardiovascular disease, active peptic ulcer, uncontrolled hypertension, uncontrolled diabetes or insulin dependent patients or any medical condition that may interfere with the completion of the clinical study.
    6. Known allergies, hypersensitivity, or intolerance to GV1001 or similar products or excipients.
    7. History of alcohol, substance abuse or dependence as per DSM-V criteria (except nicotine dependence) within the last 2 years.
    8. Concurrent malignancies or invasive cancers diagnosed within the past 5 years except for adequately treated non-metastatic basal cell carcinoma or squamous cell carcinoma of skin, in situ carcinoma of the uterine cervix or non metastatic prostate cancer.
    9. Sexually-active WOCBP or man capable of fathering a child who do not consent to using medicinally acceptable contraception (such as surgical sterilization, intrauterine contraceptive device, condom or diaphragm, an injectable or inserted contraceptive) during the study and for 3 months after the last dose of study treatment.
    10. Pregnant, breast feeding, or planning a pregnancy or fathering a child while enrolled in the study or for 3 months after the last dose of study treatment.
    11. Use of anxiolytics, narcotics, or sleep aids in a manner that would interfere with cognitive testing, in the opinion of the Investigator. Atypical antipsychotics may be used at the discretion of the Investigator. Tricyclic antidepressants and monoamine oxidase (MAO) inhibitors are prohibited
    12. Previous treatment with GV1001.
    13. Received an investigational product for AD within the last 6 months.
    14. Participated in another clinical study within 4 weeks prior to this study.
    15. Treated with aducanumab or participated in a clinical study with aducanumab.
    16. Renal impairment (creatinine clearance [CrCL] <30 mL/min).
    17. Severe liver dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the upper limit of normal [ULN]).
    18. Body weight =35 kg.
    19. Resides in a moderate to high dependency continuous care facility (residence in low grade assisted living facility where there is sufficient autonomy to permit valid evaluation of activities of daily living is allowed).
    20. Any other reason that in the opinion of the Investigator would make the participant ineligible to participate or to complete this study.
    1. qualsiasi altra causa di demenza dimostrata dai riscontri della RM/TAC nei 2 anni precedenti lo screening (o allo screening) e dell’esame neurologico allo screening e il Giorno 1;
    • Possibile, probabile o definita demenza vascolare secondo i criteri dell'Istituto Nazionale dei Disturbi Neurologici e dell'Ictus e dell'Associazione Internazionale per la Ricerca e l'Enseignement in Neuroscienze (NINDS-AIREN).
    • • Evidenza di anomalia significativa che suggerirebbe un'altra potenziale eziologia per la demenza (ad es. evidenza di contusione cerebrale, encefalomalacia, aneurisma, malformazione vascolare, >5 microemorragie, macroemorragia, singolo infarto >1 cm3).
    • • Altre malattie del sistema nervoso centrale tra cui demenza cerebrovascolare, parkinsonismo, malattia di Huntington, ematoma subdurale, idrocefalo normoteso, tumore al cervello, malattia di Creutzfeldt-Jakob)
    2. presenza o anamnesi di schizofrenia o disordine bipolare; o qualsiasi altra malattia psichiatrica clinicamente significative (es., schizofrenia, disturbo affettivo bipolare) che, secondo il parere dello Sperimentatore, impediscano la partecipazione, o potrebbero confondere l’interpretazione dell’effetto del farmaco o delle valutazioni affettive e cognitive o la sicurezza dei partecipanti; OPPURE la presenza o la storia di tentativi di suicidio o di ideazione suicidaria evidenziata dall'approvazione degli elementi 4 o 5 del C-SSRS allo screening o al giorno 1, dall'approvazione di qualsiasi elemento di comportamento suicidario nel modulo C-SSRS dall'ultima visita al giorno 1, o qualsiasi suicidio tentativo entro 2 anni prima dello screening.
    3. riscontri delle analisi di vitamina B12, acido folico, test sierologici per la sifilide ed ormone tireostimolante (TSH) che si ritiene contribuiscano alla gravità della demenza o causino la demenza. I partecipanti potrebbero essere arruolati se secondo il parere medico dello Sperimentatore, i valori di laboratorio anormali non sono la causa dei sintomi cognitivi;
    4. anamnesi di crisi convulsive note o sospette, incluse crisi convulsive febbrili (escluse crisi convulsive infantili autolimitanti), un’anamnesi di trauma cranico significativo con perdita di coscienza o recente stato di incoscienza per motivi inspiegabili;
    5. malattia cardiovascolare acuta o instabile, ulcera peptica attiva, ipertensione non controllata, diabete non controllato o pazienti insulino-dipendenti o qualsiasi altra patologia medica che potrebbe interferire con il completamento dello studio clinico;
    6. allergie, ipersensibilità o intolleranza note a GV1001 o a prodotti simili o ai suoi eccipienti;
    7. anamnesi di dipendenze o abuso di alcol o sostanze stupefacenti in base ai criteri DSM-V (salvo dipendenza da nicotina) negli ultimi 2 anni;
    8. neoplasie maligne concomitanti o tumori invasivi diagnosticati negli ultimi 5 anni, salvo per carcinoma a cellule squamose o carcinoma basocellulare della pelle non metastatico adeguatamente trattato, carcinoma in situ della cervice uterina o cancro della prostata non metastatico;
    9. donne in età fertile sessualmente attive o uomini in grado di procreare che non accettano di utilizzare metodi contraccettivi clinicamente accettabili (come sterilizzazione chirurgica, dispositivo contraccettivo intrauterino, preservativo o diaframma, un contraccettivo iniettabile o inserito) durante lo studio e per 3 mesi dopo l’ultima dose di trattamento in studio;
    10. donne in gravidanza, che allattano o che pianificano una gravidanza o uomini che intendono concepire un figlio durante l’arruolamento nello studio o entro 3 mesi dall'ultima dose di trattamento in studio;
    11. uso di ansiolitici, narcotici o sonniferi con una modalità che interferirebbe con i test cognitivi, secondo il parere dello Sperimentatore. Gli antipsicotici atipici possono essere utilizzati a discrezione dello Sperimentatore. Gli antidepressivi triciclici e gli inibitori delle monoamino ossidasi (IMAO) sono proibiti;
    12. trattamento precedente con GV1001;
    13. trattamento con un prodotto sperimentale per l’AD negli ultimi 6 mesi;
    14. partecipazione a un altro studio clinico nelle 4 settimane precedenti questo studio;
    15. trattamento con aducanumab o partecipazione a un altro studio clinico con aducanumab;
    16. insufficienza renale (clearance della creatinina [CrCL] <30 ml/min);
    17. grave disfunzione epatica (alanina aminotransferasi [ALT] o aspartato aminotransferasi [AST] >2 volte il limite superiore della norma [ULN]);
    18. peso corporeo =35 kg;
    19. residenza in un’unità di cura continuativa ad alta o moderata dipendenza (la residenza in case di riposo con assistenza di basso grado dove vi è sufficiente autonomia per permettere una valutazione valida delle attività di vita quotidiana è consentita);
    20. qualsiasi altro motivo che, secondo il parere dello Sperimentatore, renderebbe il soggetto non idoneo/a a partecipare o a completare questo studio.
    E.5 End points
    E.5.1Primary end point(s)
    - Change from baseline in ADAS-Cog11 score at Week 52
    - Adverse events (AEs), laboratory test results (hematology, serum chemistry, and urinalysis), ECG findings, and vital signs measurements (pulse rate, blood pressure, respiratory rate, body temperature). Suicidal ideation and behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C SSRS)
    - Variazione rispetto al basale nel punteggio ADAS-Cog11 alla Settimana 52
    - Eventi avversi (EA), risultati dei test di laboratorio (ematologia, ematochimica e analisi delle urine), risultati dell’ECG, e misurazione dei parametri vitali (polso, pressione sanguigna, frequenza respiratoria e temperatura corporea). L’ideazione e il comportamento suicidari saranno valutati utilizzando la Scala della Columbia University per la valutazione della gravità del rischio di suicidio (C-SSRS)
    E.5.1.1Timepoint(s) of evaluation of this end point
    - Week 52
    - during study duration
    - Settimana 52
    - durante tutta la durata dello studio
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints:
    • Clinical worsening, defined as = 4 points change from baseline in the ADAS-cog11 score at Week 12, Week 26, Week 38, and Week 52
    • Change from baseline in A-IADL-Q score at Week 12, Week 26, Week 38 and Week 52
    • Change from baseline in NPI score at Week 12, Week 26, Week 38, and Week 52
    • Change from baseline in MMSE score at Week 12, Week 26, Week 38, and Week 52
    • Change from baseline in CDR-SB score at Week 12, Week 26, Week 38, and Week 52
    • Change from baseline in ADCS-CGIC/CIBIC-Plus score at Week 12, Week 26, Week 38, and Week 52
    • Change from baseline in QoL-AD score at Week 26 and Week 52
    Gli endpoints di efficacia secondari:
    • Peggioramento clinico, definite come il cambio = 4 punti dallo stato base nel punteggio ADAS-cog11 alla Settimana 12, Settimana 26, Settimana 38, e Settimana 52
    • Cambio dallo stato base nel punteggio A-IADL-Q alla Settimana 12, Settimana 26, Settimana 38 e Settimana 52
    • Cambio dallo stato base nel punteggio NPI alla Settimana 12, Settimana 26, Settimana 38, e Settimana 52
    • Cambio dallo stato base nel punteggio MMSE alla Settimana 12, Settimana 26, Settimana 38, e Settimana 52
    • Cambio dallo stato base nel punteggio CDR-SB alla Settimana 12, Settimana 26, Settimana 38, e Settimana 52
    • Cambio dallo stato base nel punteggio ADCS-CGIC/CIBIC-Plus alla Settimana 12, Settimana 26, Settimana 38, e Settimana 52
    • Cambio dallo stato base nel punteggio QoL-AD alla Settimana 26 e Settimana 52
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 12, week 26, Week 38 and Week 52
    Settimana 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Immunogenicità
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    Finland
    France
    Italy
    Netherlands
    Poland
    Portugal
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient last visit
    Ultima visita dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days6
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 60
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 120
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Patients with the condition tested might not be able to give consent due to Alzheimer's
    I pazienti con la condizione di malattia testata potrebbero non essere in grado di dare il consenso a causa della malattia di Alzheimer
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state16
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 180
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    standard of care
    standard of care
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-02-16
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-12-16
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:30:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA